The Bookrunner, the Trust Shares, and the Downgrade IB Wants Delayed
Marcus Hale covers medical technology at a 400-rep firm. His spouse controls a trust holding 1,200 shares of Verity Health Systems, one of Marcus's covered names (about $72,000). The firm is one of two bookrunners on a $500 million Verity convertible notes offering that prices in five days. The head of investment banking emails Marcus a "research angle" slide deck and asks him to join tomorrow's pitch call with Verity's CFO, and to "keep the rating where it is until this thing is done." Meanwhile, Marcus's own model - after a reimbursement rule change - now supports a downgrade from Buy to Hold. Marcus mentions to a colleague that he'd like to trim the trust position before he finalizes the note.
1. Can Marcus join the pitch call and use the IB deck? What limits apply?
Read the worked answer
Join: possibly. Use the deck: not as a shortcut.
- Limited analyst participation in IB pitches is permitted under FINRA Rule 2241 only within firm procedures: no solicitation, no discussion of specific transaction terms or of the research rating, and no use of the analyst as a sweetener. The analyst cannot be evaluated or paid on deal success.
- The deck is IB marketing material. It may contain deal terms and projections that are material nonpublic information. Importing it into a research report risks publishing MNPI and turns research into a syndicate document. Marcus may read it as background but must build his own analysis and cannot repeat deal-specific content.
- IB may not direct his conclusion, preview his draft for tone, or set his timeline. The instruction to "keep the rating where it is" is a request Marcus must refuse and document.
- If he attends, the firm should have a record of the invitation, his role, and the fact that research content was not discussed.
2. What must happen with the trust shares and his stated intention to trim the position before finalizing the downgrade?
Read the worked answer
This is the most serious fact in the case.
- Disclosure and pre-clearance. A spouse-controlled trust is a household interest. Holdings must be reported to the firm, pre-cleared, and disclosed in reports as required for analyst (and household) ownership of the subject company's securities.
- No trading ahead of the change. Selling covered shares while in possession of an imminent, unpublished downgrade is front-running the firm's own research. It is inconsistent with just and equitable principles of trade, breaches the firm's information-barrier and personal-trading procedures, and can expose both Marcus and the firm to fraud-based claims by the buyers of those shares.
- Practically: the firm should place the name on a restricted/blackout list immediately, prohibit any sale by Marcus or the trust until after publication plus the firm's cooling-off period, and consider requiring an orderly disposition plan approved by Compliance. He must not delay or soften the note to free up the trade.
- Escalation. The colleague who heard the remark has an obligation to raise it; a supervisor who learns of it and does nothing is a failure-to-supervise problem.
3. How should Marcus handle the downgrade given the pending deal and the quiet period? Draft the reasoning he should give his supervisor.
Read the worked answer
Two separate clocks must not be confused.
- Quiet period. As a managing underwriter, the firm is restricted from publishing a research report on Verity during the applicable post-offering quiet period. If publication would fall inside that window, the report waits - but the wait must be tied to the rule's dates, documented by Compliance, and end the day the window opens. It is not "until the deal is done," and it is not extended by IB preference.
- IB influence. Outside the window, a request to hold or soften a rating to help a live deal is precisely the conduct Rule 2241 prohibits: no implied promise of favorable research, no IB control over content or timing. The note is published on its merits once permitted.
- Protection. Marcus should put the request in writing to his supervisor and the CCO, note the rule-based reason for any delay, and confirm that his compensation and coverage are not affected. Retaliation against an analyst for a negative view - including coverage reassignment - is itself prohibited.
- Consistency. The downgrade, the trust holdings, and any delay all need to be reflected correctly in the report's disclosures so a reader can see the full conflict picture.